This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Patient Advocate Foundation And Jazz Pharmaceuticals Announce Partnership For Narcolepsy CareLine

HAMPTON, Va. and DUBLIN, July 19, 2012 /PRNewswire/ --  Patient Advocate Foundation (PAF) and Jazz Pharmaceuticals  (Nasdaq: JAZZ)have partnered to launch the Narcolepsy CareLine, a dedicated hotline (866-538-7617) providing support services to the narcolepsy patient community.  The hotline is staffed by a team of professionals from PAF, a national non-profit organization with experience in customized patient-focused case management.

Narcolepsy is a chronic neurologic brain disorder caused by the brain's inability to regulate sleep-wake cycles normally, and can affect all aspects of a patient's life, emotionally, physically, socially and academically. Impacting 1 in approximately 2,000 people in the United States of America, narcolepsy symptoms can lead to a variety of complications, such as limitations on education and employment opportunities, driving or machine accidents, difficulties at work resulting in disability, forced retirement or job dismissal and depression. It is estimated today that between 125,000 and 200,000 people are affected by this disorder in the United States.

Through the Narcolepsy CareLine, narcolepsy patients, their caregivers and healthcare providers can now receive individualized support services including assistance with insurance appeals, guidance with insurance benefit reimbursement and benefit programs, assistance with Medicare, Medicaid and Disability screening and enrollment, as well as referrals to local, state or federal resources.  Further details, web contact forms and a full list of services available through the Narcolepsy CareLine can be found by calling 1-866-538-7617 or at

"We are so pleased to have this opportunity to support narcolepsy patients by providing a resource to assist with the potential access barriers and practical challenges that they face," says Beth Patterson, president of mission delivery of Patient Advocate Foundation. "Both patients and providers will benefit from the guidance and expertise of the case managers at Patient Advocate Foundation." 

Bruce Cozadd, chairman and chief executive officer of Jazz Pharmaceuticals, a specialty biopharmaceutical company stated, "Our company is committed to forming partnerships and broadening the services offered to patients with narcolepsy. The Narcolepsy CareLine is a great example of how two organizations can come together on behalf of patients."

About Patient Advocate Foundation

PAF is a national non-profit organization that seeks to safeguard patients through effective mediation assuring access to care, maintenance of employment and preservation of financial stability relative to their diagnosis of chronic, life threatening or debilitating disease. Patient Advocate Foundation has been consistently rated as a 4-star "exceptional" charity by Charity Navigator, the foremost independent evaluator of charities in the United States. For more information about Patient Advocate Foundation, please visit  

About Jazz Pharmaceuticals (Nasdaq: JAZZ)

Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain, psychiatry and women's health. The company's U.S. marketed products in these areas include: Xyrem® (sodium oxybate), Erwinaze™ (asparaginase Erwinia chrysanthemi), Prialt® (ziconotide intrathecal infusion), FazaClo® (clozapine USP) HD and LD, Luvox CR® (fluvoxamine maleate) and Elestrin® (estradiol gel 0.06%). Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by an international division, EUSA Pharma.

SOURCE Jazz Pharmaceuticals

Copyright 2011 PR Newswire. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,868.06 +77.87 0.46%
S&P 500 1,990.38 +10.46 0.53%
NASDAQ 4,772.20 +23.8390 0.50%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs